W El-Matary et al. JPGN 2020; 71: 740-743. Discontinuation of Immunosuppressive Medications in Children With Inflammatory Bowel Disease on Combination Therapy
This study looked at 105 patients receiving combination therapy; the a median duration of combination therapy was 2.1 years, with infliximab and either methotrexate (53) or azathioprine (52). 89 patients had Crohn’s disease.
- 11 (10.5%) patients experienced a clinical relapse over a median duration of follow-up of 12.0 months after stopping the immunomodulator.
- In the patients who did not relapse, the median IFX trough level at IM discontinuation was 6.2; the IFX trough level was 3.8 μg/mL in those who relapsed.
In their discussion, the authors urge caution in discontinuation of immunomodulators in those with clinically-severe Crohn’s disease and those with low infliximab levels.
Related blog posts:
- Can Therapeutic Drug Monitoring with Monotherapy Achieve Similar Results to Combination IBD Therapy?
- Combination Therapy Still Works for Inflammatory Bowel Disease (Part 1) | gutsandgrowth
- What about Combination Therapy with Adalimumab?
- Proactive Therapeutic Drug Monitoring in Pediatric Crohn’s disease -Better Outcomes | gutsandgrowth
- Combination Therapy Associated with Treatment Persistence | gutsandgrowth
- Changes in the Use of IBD Biologic Therapy | gutsandgrowth
- Should All Pediatric Patients with Crohn’s Disease Continue Combination Therapy? | gutsandgrowth
- Don’t be Fooled About Withdrawing Immunomodulator Cotherapy -Look Past the Headline
Disclaimer: This blog, gutsandgrowth, assumes no responsibility for any use or operation of any method, product, instruction, concept or idea contained in the material herein or for any injury or damage to persons or property (whether products liability, negligence or otherwise) resulting from such use or operation. These blog posts are for educational purposes only. Specific dosing of medications (along with potential adverse effects) should be confirmed by prescribing physician. Because of rapid advances in the medical sciences, the gutsandgrowth blog cautions that independent verification should be made of diagnosis and drug dosages. The reader is solely responsible for the conduct of any suggested test or procedure. This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition
Pingback: Combating Anti-Drug Antibodies with Immunomodulators in Pediatric IBD | gutsandgrowth